TCM
CNTX icon

TCG Crossover Management’s Context Therapeutics CNTX Stock Holding History

TCG Crossover Management’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.49M Hold
2,682,696
– – 0.04% 53
2026
Q1 		$7.03M Buy
+2,682,696
New +$6.26M 0.2% 43

Other funds holding CNTX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

TCG Crossover Management's CNTX Position: Q2 2026 in Review

TCG Crossover Management held its Context Therapeutics (CNTX) position steady in Q2 2026 at 2,682,696 shares worth $1.49M. The position accounts for 0.04% of the portfolio, ranked #53.

TCG Crossover Management first reported a position in CNTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $7.03M in Q1 2026. 79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • TCG Crossover Management held 2,682,696 shares of Context Therapeutics worth $1.49M as of Q2 2026.
  • TCG Crossover Management left its Context Therapeutics share count unchanged in Q2 2026.
  • Context Therapeutics made up 0.04% of TCG Crossover Management's portfolio in Q2 2026, its #53 holding.
  • TCG Crossover Management first reported a position in Context Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • TCG Crossover Management's Context Therapeutics position peaked at $7.03M in Q1 2026.
  • 79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on TCG Crossover Management's 13F filing for Q2 2026, filed 14 Aug 2026.